Report Detail

Other Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2019-2025

  • RnM3472145
  • |
  • 12 July, 2019
  • |
  • Global
  • |
  • 98 pages
  • |
  • QYResearch
  • |
  • Other

Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2019-2025

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Subretinal
      • 1.4.3 Intravitreal
      • 1.4.4 Unspecified
    • 1.5 Market by Application
      • 1.5.1 Global Gene Therapy for Age-related Macular Degeneration Market Share by Application (2014-2025)
      • 1.5.2 Monotherapy
      • 1.5.3 Combination Therapy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Gene Therapy for Age-related Macular Degeneration Market Size
    • 2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Regions
      • 2.2.1 Gene Therapy for Age-related Macular Degeneration Market Size by Regions (2014-2025)
      • 2.2.2 Gene Therapy for Age-related Macular Degeneration Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Gene Therapy for Age-related Macular Degeneration Market Size by Manufacturers
      • 3.1.1 Global Gene Therapy for Age-related Macular Degeneration Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served
    • 3.3 Key Players Gene Therapy for Age-related Macular Degeneration Product/Solution/Service
    • 3.4 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2014-2019)
    • 4.2 Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 5.2 Gene Therapy for Age-related Macular Degeneration Key Players in United States
    • 5.3 United States Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 5.4 United States Gene Therapy for Age-related Macular Degeneration Market Size by Application

    6 Europe

    • 6.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 6.2 Gene Therapy for Age-related Macular Degeneration Key Players in Europe
    • 6.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 6.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Application

    7 China

    • 7.1 China Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 7.2 Gene Therapy for Age-related Macular Degeneration Key Players in China
    • 7.3 China Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 7.4 China Gene Therapy for Age-related Macular Degeneration Market Size by Application

    8 Japan

    • 8.1 Japan Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 8.2 Gene Therapy for Age-related Macular Degeneration Key Players in Japan
    • 8.3 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 8.4 Japan Gene Therapy for Age-related Macular Degeneration Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 9.2 Gene Therapy for Age-related Macular Degeneration Key Players in Southeast Asia
    • 9.3 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 9.4 Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size by Application

    10 India

    • 10.1 India Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 10.2 Gene Therapy for Age-related Macular Degeneration Key Players in India
    • 10.3 India Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 10.4 India Gene Therapy for Age-related Macular Degeneration Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size (2014-2019)
    • 11.2 Gene Therapy for Age-related Macular Degeneration Key Players in Central & South America
    • 11.3 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Type
    • 11.4 Central & South America Gene Therapy for Age-related Macular Degeneration Market Size by Application

    12 International Players Profiles

    • 12.1 RetroSense Therapeutics
      • 12.1.1 RetroSense Therapeutics Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Gene Therapy for Age-related Macular Degeneration Introduction
      • 12.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
      • 12.1.5 RetroSense Therapeutics Recent Development
    • 12.2 REGENXBIO
      • 12.2.1 REGENXBIO Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Gene Therapy for Age-related Macular Degeneration Introduction
      • 12.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
      • 12.2.5 REGENXBIO Recent Development
    • 12.3 AGTC
      • 12.3.1 AGTC Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Gene Therapy for Age-related Macular Degeneration Introduction
      • 12.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2014-2019)
      • 12.3.5 AGTC Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
      It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market's growth.
      The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).
      According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
      In 2018, the global Gene Therapy for Age-related Macular Degeneration market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

      The key players covered in this study
      RetroSense Therapeutics
      REGENXBIO
      AGTC
      ...

      Market segment by Type, the product can be split into
      Subretinal
      Intravitreal
      Unspecified

      Market segment by Application, split into
      Monotherapy
      Combination Therapy

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players.
      To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Gene Therapy for Age-related Macular Degeneration. Industry analysis & Market Report on Gene Therapy for Age-related Macular Degeneration is a syndicated market report, published as Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Gene Therapy for Age-related Macular Degeneration market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,117.69
      4,676.54
      6,235.38
      3,472.34
      5,208.51
      6,944.68
      420,030.00
      630,045.00
      840,060.00
      268,557.90
      402,836.85
      537,115.80
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report